NASDAQ:RTTR Ritter Pharmaceuticals (RTTR) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free RTTR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.36▼$0.4050-Day Range$0.45▼$4.0952-Week Range$0.15▼$1.27Volume79,611 shsAverage Volume14.23 million shsMarket Capitalization$18.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Ritter Pharmaceuticals alerts: Email Address Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Ritter Pharmaceuticals Stock (NASDAQ:RTTR)Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.Read More Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> RTTR Stock News HeadlinesJanuary 24, 2024 | health.usnews.comDr. John D. RitterSeptember 15, 2023 | health.usnews.comKristen RitterMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.July 8, 2023 | health.usnews.comDr. Harold K. RitterJuly 1, 2023 | bizjournals.comDenver Business Journal welcomes new tech reporterApril 10, 2023 | usatoday.comJason Ritter and Drew Barrymore's raw conversation on her show may matter more than you thinkMarch 29, 2023 | thestreet.comRitter Pharmaceuticals Changing the Game With Lactose Intolerance TreatmentMarch 18, 2023 | finance.yahoo.comGlobal Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second GenomeMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.January 19, 2023 | yahoo.comMelanie Lynskey's husband Jason Ritter will join her in Yellowjackets this seasonNovember 16, 2022 | finance.yahoo.comMicrobiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsightSee More Headlines Receive RTTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RTTR CUSIPN/A CIK1460702 Webwww.ritterpharmaceuticals.com Phone310-203-1000FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,130,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.05% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book4.00Miscellaneous Outstanding Shares46,153,000Free FloatN/AMarket Cap$18.46 million OptionableNot Optionable Beta-0.43 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Ira Eliot Ritter (Age 70)Co-Founder, Exec. Chairman & Chief Strategic Officer Mr. Andrew J. Ritter (Age 36)Co-Founder, CEO, Pres, Corp. Sec. & Director Mr. Michael D. Step (Age 59)Consultant & Director Mr. John W. Beck CPA (Age 59)CPA, Chief Financial Officer Ms. Ellen F. Mochizuki (Age 52)Consultant Key CompetitorsContext TherapeuticsNASDAQ:CNTXXilio TherapeuticsNASDAQ:XLOOnconova TherapeuticsNASDAQ:ONTXTalpheraNASDAQ:TLPHFortress BiotechNASDAQ:FBIOView All Competitors RTTR Stock Analysis - Frequently Asked Questions How were Ritter Pharmaceuticals' earnings last quarter? Ritter Pharmaceuticals Inc (NASDAQ:RTTR) posted its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. When did Ritter Pharmaceuticals' stock split? Shares of Ritter Pharmaceuticals reverse split on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Ritter Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and When did Ritter Pharmaceuticals IPO? Ritter Pharmaceuticals (RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager. This page (NASDAQ:RTTR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.